days after the development of anterior neck pain. The thyroid glands were noticeably enlarged (increasing from 18 g at 131 I administration to 35 g after the development of anterior neck pain in 1 patient, and from 20 to 33 g, 21 to 39 g, 21 to 51 g, and 40 to 51 g in the other patients) and tender. The echogenicity of the thyroid parenchyma was increased, and the parenchyma was more heterogeneous. Granular hyperechoic lesions were scattered throughout the thyroid gland in the most severe case. The border between the thyroid gland and the surrounding tissue was blurred, and the surrounding tissue was hyperechoic. 
Introduction

131
I therapy is one of the main treatment options for Graves' hyperthyroidism. Although 131 I therapy is generally safe, adverse events may occur [1] . Among the adverse events, radiation thyroiditis is an acute condition occurring within 2 weeks after 131 I administration [2] . Radiation thyroiditis is asymptomatic in most patients, but painful inflammation of the thyroid gland occurs in 1% of patients with hyperthyroidism [3] . It is even rarer for radiation thyroiditis to be associated with fever. In addition, there are few reports on the ultrasonographic findings of radiation thyroiditis after 131 I therapy for Graves' hyperthyroidism [4] . We herein report 5 cases with painful radiation thyroiditis (including 2 febrile cases) after 131 I therapy for Graves' hyperthyroidism, with clinical features and serial ultrasound images.
Methods
The absorbed radiation dose of the thyroid gland was estimated by using the Quimby-Marinelli formula and thyroidal 99m Tc uptake, as previously reported [5] . The patients underwent ultrasonographic examination within 10 days prior to 131 I administration as well as after the development of painful radiation thyroiditis. Ultrasonographic evaluation of the thyroid and neck was performed with the Aplio XG, Aplio 400, or Aplio 500 systems (Toshiba Medical Systems Co., Tokyo). Intraglandular vascular flow was evaluated with Doppler color flow imaging. Thyroid weight was estimated through ultrasound as previously reported [6] . Thyroid scan and uptake were performed at 20 min after intravenous injection of 185 MBq 99m Tc-pertechnetate prior to 131 I administration on the same day. Serum levels of free thyroxine (FT4) and thyrotropin (TSH) were measured by using commercial immunoassays (Roche Diagnostics Inc., Tokyo). Serum TSH receptor antibody (TRAb) and anti-thyroid peroxidase (TPO) antibody levels were measured using commercial electrochemiluminescence immunoassays (Elecsys Anti-TSHR and Elecsys Anti-TPO; Roche Diagnostics Inc., Tokyo; reference ranges <2.0 IU/l and <16 IU/ml, respectively). In some patients, autoantibody levels to the thyroid microsomal antigen were measured by means of particle agglutination using commercial kits (Serodia-AMC; Fujirebio Inc., Tokyo; reference range less than ×100). Table 1 gives a detailed description of the clinical characteristics of all 5 patients at 131 I therapy and after radiation thyroiditis.
Case Reports
Case 1
A 50-year-old woman underwent 131 I therapy for intractable Graves' hyperthyroidism. In spite of instructions to cease methimazole (MMI) prior to 131 I administration, she had taken MMI 10 mg daily until the day of 131 I administration. She developed anterior neck pain at night on the same day of 131 I administration. The goiter was enlarged and tender. Radiation thyroiditis was treated with prednisolone 15 mg/day for 4 days. She resumed taking MMI 10 mg daily 2 days after 131 I administration.
Case 2
A 49-year-old woman underwent 131 I therapy for recurrent Graves' hyperthyroidism. MMI 10 mg daily was withdrawn 2 days prior to 131 I administration, and she began to take potassium iodide (KI) 50 mg daily to avoid exacerbation of hyperthyroidism 2 days after 131 I administration. Nine days after 131 I administration, she developed anterior neck pain and high fever. When she visited our clinic 3 days after the onset, the goiter was enlarged and tender. Radiation thyroiditis was treated with prednisolone 15 mg/day for 10 days.
Case 3
An 81-year-old woman underwent 131 I therapy for intractable Graves' hyperthyroidism (unstable thyroid function). When she underwent 131 I therapy, she was hypothyroid due to overtreatment with MMI. She stopped taking MMI 5 mg daily 2 days prior to 131 I administration and resumed MMI 5 mg every other day 2 days after 131 I administration. Three days after 131 I administration, she I administration. TRAb = TSH receptor antibody; anti-TPO = anti-thyroid peroxidase antibody; WBC = white blood cell; CRP = C-reactive protein; n.a. = not available.
a Anti-thyroid microsomal particle agglutination assay. I administration ( c ). One day after neck pain developed ( b ), the thyroid gland was clearly enlarged and the echogenicity of the thyroid parenchyma was increased. d-f Case 2: ultrasonographic images at the same day ( d ), 12 days after ( e ), and 56 days after 131 I administration ( f ). Three days after neck pain developed ( e ), a diffusely enlarged goiter with more heterogeneous internal echoes was observed. g-i Case 3: ultrasonographic images on the day ( g ), 7 days after ( h ), and 56 days after 131 I administration ( i ). Four days after neck pain developed ( h ), a diffusely enlarged goiter with relatively hyperechoic internal echoes was observed. Granular hyperechoic lesions were scattered throughout the thyroid gland. j-l Case 4: ultrasonographic images on the day ( j ), 4 days after ( k ), and 58 days after 131 I administration ( l ). One day after neck pain developed ( k ), a diffusely enlarged goiter was observed. m-o Case 5: ultrasonographic images at the same day ( m ), 10 days after ( n ), and 41 days after 131 I administration ( o ). On the day the neck pain developed ( n ), the thyroid gland was enlarged and the echogenicity of the thyroid parenchyma was increased. The border between the thyroid gland and the surrounding tissue became blurred and irregular (cases 1-5), and the surrounding tissue was hyperechoic (cases 3-5) within several days of neck pain development ( b , e , h , k , n ). 204 developed anterior neck pain and high fever. Since the anterior neck pain and high fever continued, she visited our clinic 4 days after the onset. The goiter was visibly enlarged and tender. She took prednisolone 15 mg/day for only 2 days, although it was prescribed for 7 days.
Case 4
A 76-year-old woman underwent 131 I therapy for recurrent Graves' hyperthyroidism. MMI 10 mg daily was withdrawn 2 days prior to 131 I administration, and she resumed MMI 5 mg daily 2 days after 131 I administration. Three days after 131 I administration, she developed anterior neck pain. When she visited our clinic the day following the onset, the goiter was enlarged and tender. Radiation thyroiditis was treated with prednisolone 15 mg/day for 7 days.
Case 5
A 60-year-old man underwent 131 I therapy for Graves' hyperthyroidism. Because of MMI-induced liver injury, he had been switched to KI. KI 50 mg daily was withdrawn 5 days prior to 131 I administration, and he resumed KI 50 mg daily 2 days after 131 I administration. Ten days after 131 I administration, he developed anterior neck pain and swelling. When he visited our clinic on the same day of the onset, the goiter was enlarged and tender. Because of his diabetes and relatively mild neck pain, radiation thyroiditis was treated with acetaminophen.
The present cases included 4 women and 1 man, and all were nonsmokers who had been treated with 481 MBq of 131 I. At the time of 131 I administration, the patients' estimated thyroid gland weights were 18-40 g, and thyroidal 99m Tc uptake was increased to 4.1-9.5% (reference range 0.5-4.0%). One patient (case 3) had overt hypothyroidism. TRAb and anti-TPO antibody were all positive. Anterior neck pain developed 0-10 days after 131 I administration. Two patients developed high fever along with the anterior neck pain. The clinical examinations were conducted 0-4 days after the development of anterior neck pain. Goiters were enlarged 1.3-to 2.4-fold and were tender. Serum thyroid hormone levels were increased from those seen just prior to 131 I administration in cases 2 and 3. Serum C-reactive protein levels (reference range <0.5 mg/dl) were elevated in all 3 patients who underwent examination. All 5 patients were diagnosed with 131 I-induced radiation thyroiditis based on the clinical course, thyroid tenderness, and ultrasonographic changes of the thyroid. Four were treated with prednisolone, and the administration periods were determined by each attending physician. The patients' anterior neck pain and fever were eliminated within 1 or 2 days after taking prednisolone. Their goiters shrank relatively rapidly, and they all eventually developed hypothyroidism, after which replacement of L -thyroxine was initiated. Figure 1 shows ultrasonographic images from the present patients before and after 131 I administration. At 131 I administration, the thyroid glands were diffusely enlarged with a heterogeneous and coarse echotexture; 1-4 days after the development of anterior neck pain, the thyroid glands were clearly enlarged. The echogenicity of the thyroid parenchyma was increased, and the parenchyma was more heterogeneous. Especially in case 3, granular hyperechoic lesions were scattered throughout the thyroid gland. The border between the thyroid gland and the surrounding tissue was blurred and irregular (cases 1-5), and the surrounding tissue was hyperechoic (cases 3-5). Hypervascularity of the thyroid glands diminished shortly after the development of painful radiation thyroiditis ( fig. 2 ) . The thyroid glands also became hypoechoic as they shrank over a period of a few months. The border between the thyroid gland and the surrounding tissue became clear, and the echogenicity of the surrounding tissue normalized. The estimated weights of the thyroid decreased to less than 10 g within 6 months during the follow-up.
Discussion
During the last 5 years in which the 5 present patients were treated, we administered 131 I therapy to a total of 927 patients with Graves' hyperthyroidism. Therefore, the incidence of painful radiation thyroiditis after 131 I therapy In conclusion, the development of painful radiation thyroiditis should be considered for patients with Graves' hyperthyroidism after 131 I therapy. 131 I-induced radiation thyroiditis is associated with characteristic findings on ultrasonography.
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